Sarepta Therapeutics upgraded by Mizuho with a new price target
$SRPT
Biotechnology: Pharmaceutical Preparations
Health Care
Mizuho upgraded Sarepta Therapeutics from Neutral to Outperform and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2025 | $26.00 | Neutral → Outperform | Mizuho |
| 9/22/2025 | $50.00 | Market Perform → Outperform | BMO Capital Markets |
| 7/29/2025 | $22.00 | Underweight → Equal Weight | Barclays |
| 7/29/2025 | $13.00 | Mkt Perform | Bernstein |
| 7/29/2025 | $37.00 | Perform → Outperform | Oppenheimer |
| 7/29/2025 | $24.00 | Underweight → Neutral | Analyst |
| 7/29/2025 | $5.00 | Sell | H.C. Wainwright |
| 7/28/2025 | $10.00 | Equal Weight → Underweight | Barclays |
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling
For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. Elevidys was previously approved under accelerated approval for amb
Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
SCHEDULE 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary endpoint, results indicate positive and encouraging trends favoring therapy at 96 weeks Sarepta reports that the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint ESSENCE supported favorable safety profile of AMONDYS 45 and VYONDYS 53 The Company intends to schedule a meeting with FDA to discuss path to a traditional approval based on the positive risk-benefits of the thera
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2025 financial results and recent corporate developments. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register
Funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today launched nine new single stock leveraged ETFs, seven of which are first-to-market strategies. The funds, all listed on Cboe, seek to deliver twice (200%) the daily performance of a specific underlying stock. The following ETFs are first-to-market exposures: Tradr 2X Long BLSH Daily ETF (Cboe: BLSX) – tracks Bullish Limited (NYSE:BLSH)Tradr 2X Long DASH Daily ETF (Cboe: DASX) – tracks DoorDash, Inc. (NASDAQ:DASH)Tradr 2X Long FLY Daily ETF (Cboe: FLYT) – tracks Firefly Aerospace, In
Mizuho upgraded Sarepta Therapeutics from Neutral to Outperform and set a new price target of $26.00
BMO Capital Markets upgraded Sarepta Therapeutics from Market Perform to Outperform and set a new price target of $50.00
Barclays upgraded Sarepta Therapeutics from Underweight to Equal Weight and set a new price target of $22.00
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary endpoint, results indicate positive and encouraging trends favoring therapy at 96 weeks Sarepta reports that the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint ESSENCE supported favorable safety profile of AMONDYS 45 and VYONDYS 53 The Company intends to schedule a meeting with FDA to discuss path to a traditional approval based on the positive risk-benefits of the thera
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2025 financial results and recent corporate developments. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register
ELEVIDYS shipments have resumed for ambulatory individuals living with Duchenne following notification from the U.S. Food and Drug Administration (FDA); continuing to work with FDA on safety labeling process and risk-mitigation approach for non-ambulatory individuals Net product revenues for the second quarter 2025 totaled $513.1 million, a 42% increase over the same quarter of the prior year Previously announced restructuring advancing as planned; on track to realize over $100 million in cost savings through the end of 2025 Multiple clinical data readouts and milestones expected in 2025 and into early 2026 to support siRNA franchise - FSHD, DM1, SCA2, and Huntington's Disease
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior
- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)
SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)